PUBLISHER: The Business Research Company | PRODUCT CODE: 1939186
PUBLISHER: The Business Research Company | PRODUCT CODE: 1939186
An absorbable hemostat is a medical device used to control bleeding during surgical procedures. It is designed to enhance blood clotting and stabilize bleeding tissues. Made from materials that can be gradually broken down and absorbed by the body, an absorbable hemostat eliminates the need for surgical removal.
The main types of absorbable hemostats include thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, gelatin-based hemostats, collagen-based hemostats, and others. Thrombin-based hemostats contain thrombin, an enzyme that aids blood clotting by converting fibrinogen into fibrin. These hemostats are used in various surgical fields, including neurosurgery, orthopedic surgery, general surgery, and reconstructive surgery, and are utilized by end-users such as hospitals, clinics, ambulatory surgical centers, and others.
Tariffs are influencing the absorbable hemostats market by increasing import costs for biomaterials, collagen substrates, cellulose fibers, and sterile medical-grade polymers used in thrombin-based, gelatin-based, collagen-based, and oxidized regenerated cellulose hemostat products. These impacts are more pronounced in regions that depend heavily on cross-border sourcing and contract manufacturing, particularly across North America, Europe, and Asia-Pacific surgical product supply chains. Higher duties have raised procurement costs for hospitals, clinics, and ambulatory surgical centers; however, they are also encouraging localization of production, regional material sourcing, and innovation in cost-efficient absorbable hemostat formulations.
The absorbable hemostats market research report is one of a series of new reports from The Business Research Company that provides absorbable hemostats market statistics, including absorbable hemostats industry global market size, regional shares, competitors with a absorbable hemostats market share, detailed absorbable hemostats market segments, market trends and opportunities, and any further data you may need to thrive in the absorbable hemostats industry. This absorbable hemostats market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The absorbable hemostats market size has grown strongly in recent years. It will grow from $3.37 billion in 2025 to $3.63 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increasing volume of neurosurgery and orthopedic surgery procedures, rising demand for intraoperative bleeding control products, growing adoption of oxidized regenerated cellulose and gelatin-based hemostats, expansion of hospital surgical infrastructure and operating rooms, increasing clinical acceptance of absorbable biomaterial hemostats.
The absorbable hemostats market size is expected to see strong growth in the next few years. It will grow to $4.96 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to rising usage of advanced thrombin and collagen-based formulations, growing shift toward minimally invasive and reconstructive surgeries, increasing investment in bioabsorbable and hybrid hemostat innovation, expansion of ambulatory surgical center procedure volumes, rising focus on reducing surgical complications and recovery time. Major trends in the forecast period include increasing development of bioengineered absorbable hemostat materials for enhanced tissue compatibility, rising adoption of advanced collagen, gelatin, and thrombin-based hemostats in complex surgical procedures, growing preference for multifunctional hemostatic products supporting rapid clot stabilization and wound healing, expanding utilization of absorbable hemostats in minimally invasive and reconstructive surgeries, increasing clinical focus on hemostats designed to reduce post-operative complications and surgical bleeding risks.
The rising number of surgical procedures is anticipated to drive the growth of the absorbable hemostats market in the coming years. Surgical procedures are medical interventions performed to diagnose, treat, or manage health conditions by physically altering tissues or organs through incisions or other techniques. The growth in surgical procedures is driven by increasing demand for advanced medical treatments, an aging population, and technological advancements that allow for more complex and minimally invasive surgeries. Absorbable hemostats are used during surgical procedures to control bleeding and support clot formation while being naturally absorbed by the body, thereby reducing the need for follow-up interventions and lowering the risk of postoperative complications. For example, in April 2025, according to the British Association of Aesthetic Plastic Surgeons, a UK-based professional organization, a total of 25,972 surgical procedures were performed in 2023, with women accounting for 93% of all cosmetic surgeries, while men represented the remaining 7%. Consequently, the growing volume of surgical procedures is contributing to the expansion of the absorbable hemostats market.
Major companies in the absorbable hemostats market are concentrating on the development of advanced products, such as absorbable hemostatic powders, to deliver rapid and effective bleeding control during surgical procedures. Absorbable hemostatic powder is a medical product designed to control bleeding by accelerating clot formation at the injury site and is naturally absorbed by the body after achieving its purpose. For instance, in July 2023, Baxter International Inc., a US-based healthcare company, introduced PERCLOT absorbable hemostatic powder. PERCLOT granules feature a distinctive molecular structure that quickly absorbs water, forming a gel-like adhesive matrix that creates a mechanical barrier to bleeding by encouraging the accumulation of platelets, red blood cells, and coagulation proteins such as thrombin and fibrinogen. This capability improves clinicians' ability to manage a wider range of intraoperative bleeding scenarios, helping reduce blood transfusion requirements, minimize major complications, and lower overall treatment costs.
In April 2024, Integra LifeSciences Holdings Corporation, a US-based science company, acquired Acclarent Inc. for an undisclosed amount. This acquisition is intended to strengthen Integra LifeSciences' position in the ENT surgical interventions market by incorporating Acclarent's innovative product portfolio. The expansion is expected to create new growth opportunities and further enhance the company's market presence. Acclarent Inc. is a US-based healthcare company specializing in the development of absorbable hemostats.
Major companies operating in the absorbable hemostats market are Johnson & Johnson, Medtronic Plc, Baxter International Inc., B. Braun Melsungen AG, Integra LifeSciences, Acelity, Meril Life Sciences Pvt. Ltd., Gelita AG, CryoLife Inc., Anika Therapeutics Inc., Z-Medica LLC, Cohera Medical Inc., Marine Polymer Technologies Inc., Curasan AG, Hemostasis LLC, Arch Therapeutics Inc., Cura Medical, FzioMed Inc., Guizhou Jin Jiu Biotech Co. Ltd., Omrix Biopharmaceuticals Inc.
North America was the largest region in the absorbable hemostats market in 2025. The regions covered in the absorbable hemostats market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the absorbable hemostats market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The absorbable hemostats market consists of sales of fibrin sealants, hemostatic powders, absorbable sponges, hemostatic plugs and absorbable mats. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Absorbable Hemostats Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses absorbable hemostats market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for absorbable hemostats ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The absorbable hemostats market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.